NANOGYRE
ActiveSummary
NANOGYRE has been active since 2020 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €12k and a net result of €-6k. Equity is growing by ~45% per year across the filed fiscal years. Its solvency ranks better than 43% of 524 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 1.2% (low).
Checked score
Score 2025
Axes · tick = 2024
Profitability48▲+48
Solvency80▼-9
Growth78▲+26
Track record100
Bankruptcy probability, 12 months
1.2%
Low
0%0.5%1.5%4%10%≥ 25%
Credit up to €500 at 30 days acceptable
Liquidity short (current ratio 0.1 against 0.09 in 2024; short-term debt: 45.5% and cash: 4.7% of total assets), and 45.5% of the assets are financed with debt.
Credit check for your own amount and term
Signals
Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Limited track record
This company has not been active as long as an established one and statistically fails somewhat more often.
KBO · incorporation dateAge against the risk zone
lowers risk · Lower-failure-rate sector
In this sector companies fail less often than the Belgian average.
Gazette · bankruptcies per sector, NACE 72
Relative position
BE, all sectors
reference
Scientific research and development (NACE 72)
about 30% fewer bankruptcies
← fewer bankruptcies
more bankruptcies →
raises risk · Annual accounts: weaker financial profile
The latest annual accounts show a weaker profile in solvency, result or liquidity than companies that stay afloat.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
54.5%
Return on assets
-27%
Age of the figures
9 mo
raises risk · Persistent losses
Two consecutive loss-making years (2024 and 2025); equity is also lower. May indicate structural pressure on profitability.
NBB · annual accounts 2025Net result per financial year
2122232425
2021 to 2025 · latest year €-6k
neutral · Filed after the deadline
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 28-08-2026, 28 days later. For context: 47% of the Belgian market files late and the whole 1-to-90-day band measures 2.0% abnormal legal state against a 1.66% average. We show this as a fact and do not score it.
NBB · 5 filingsDeviation from the deadline
2025
28 d late
2024
53 d late
2023
27 d late
2022
28 d late
2021
303 d late
← before the deadline
after the deadline →
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
25-09-2026 today31-12-2026 close31-07-2027 deadline
Financials · fiscal year 2025, micro schema
Turnover
Not included in this filing
EBIT margin
Not included in this filing
Net result
€-6k▲ 62.1%
2024 · €-16k
2021: €-8k
2022: €-1k▲ +82.7% vs 2021highest in 5 years
2023: €-13k▼ -854% vs 2022
2024: €-16k▼ -23.3% vs 2023lowest in 5 years
2025: €-6k▲ +62.1% vs 2024
2021 → 2025
Working capital
€-9k▲ 1.2%
2024 · €-9k
2021: €-8khighest value
2023: €-48klowest value
2024: €-9k▲ +80.8% vs 2023
2025: €-9k▲ +1.2% vs 2024
2021 → 2025
Trend over the years
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20212022202320242025Trend
Equity€-6k-€-7k▼ 23.2%€-20k▼ 180%€18k€12k▼ 33.1%
2021: €-6k
2022: €-7k▼ -23.2% vs 2021
2023: €-20k▼ -180% vs 2022lowest in 5 years
2024: €18k▲ +191% vs 2023highest in 5 years
2025: €12k▼ -33.1% vs 2024
Operating result€-8k-€-1k▲ 83.7%€-13k▼ 893%€-16k▼ 25.2%€-6k▲ 64.3%
2021: €-8k
2022: €-1k▲ +83.7% vs 2021highest in 5 years
2023: €-13k▼ -893% vs 2022
2024: €-16k▼ -25.2% vs 2023lowest in 5 years
2025: €-6k▲ +64.3% vs 2024
Net result€-8k-€-1k▲ 82.7%€-13k▼ 854%€-16k▼ 23.3%€-6k▲ 62.1%
2021: €-8k
2022: €-1k▲ +82.7% vs 2021highest in 5 years
2023: €-13k▼ -854% vs 2022
2024: €-16k▼ -23.3% vs 2023lowest in 5 years
2025: €-6k▲ +62.1% vs 2024
Result per fiscal year
Operating resultNet result
The operating result stays negative: a loss of €6k in 2025 against €16k in 2024; the loss shrinks.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €21k
Fixed assets
€20k ▼ 21.8%
Current assets
€1k ▲ 11.5%
Equity and liabilities €22k
Equity
€12k ▼ 33.1%
Debt
€10k =
Debt's share of the balance-sheet total rises from 35.8% to 45.5%. Equity is lower.
Key figures and ratios
EBITDA
€2k▲
2024 · €-8k
Cash flow
€2k▲
2024 · €-9k
Current ratio
0.10▲
2024 · 0.09
Debt to equity
0.83▲
2024 · 0.56
ROE
-49.6%▲
2024 · -87.5%
ROA
-27.0%▲
2024 · -56.2%
Interest coverage
5.82▲
2024 · -95.86
Debt ≤ 1 year
€10k=
2024 · €10k
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Filed annual accounts As filed with the NBB · 2025 against 2024 · 30 lines
Balance sheet
Code20242025
Assets
Total assets20/58€28k€22k▼
Formation expenses20€2k€1k▼
Fixed assets21/28€26k€20k▼
Intangible fixed assets21€24k€19k▼
Tangible fixed assets22/27€1k€646▼
Plant, machinery and equipment23€366€33▼
Furniture and vehicles24€853€613▼
Financial fixed assets28€650-
Current assets29/58€935€1k▲
Cash at bank and in hand54/58€935€1k▲
Equity and liabilities
Total equity and liabilities10/49€28k€22k▼
Equity10/15€18k€12k▼
Contributions10/11€56k€56k=
Profit (loss) carried forward14€-38k€-44k▼
Amounts payable17/49€10k€10k=
Amounts payable within one year42/48€10k€10k=
Other amounts payable47/48€10k€10k=
Income statement
Code20242025
Goods, raw materials, services and sundry goods60/61€7k-
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€7k€8k▲
Other operating charges640/8€50€1k▲
Non-recurring operating charges66A€2k-
Gross operating margin9900€-7k€3k▲
Operating profit (loss)9901€-16k€-6k▲
Financial charges65/66B€89€379▲
Recurring financial charges65€89€379▲
Profit (loss) for the period before taxes9903€-16k€-6k▲
Profit (loss) for the period9904€-16k€-6k▲
Profit (loss) for the period to be appropriated9905€-16k€-6k▲
Appropriation of the result
Profit (loss) to be appropriated9906€-38k€-44k▼
Profit (loss) brought forward from the previous period14P€-22k€-38k▼
The notes to these accounts (10 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Accounts by statement
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Non-recurring operating income76A | - | €84 | - | - | - | - |
| Goods, raw materials, services and sundry goods60/61 | €3k | €742 | €9k | €7k | - | - |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €602 | €560 | €3k | €7k | €8k | ▲ 7.8% |
| Other operating charges640/8 | €4k | €50 | €500 | €50 | €1k | ▲ 1,900% |
| Non-recurring operating charges66A | - | - | - | €2k | - | - |
| Gross operating margin9900 | €-3k | €-658 | €-9k | €-7k | €3k | ▲ 148% |
| Operating profit (loss)9901 | €-8k | €-1k | €-13k | €-16k | €-6k | ▲ 64.3% |
| Financial charges65/66B | €42 | €80 | €272 | €89 | €379 | ▲ 328% |
| Recurring financial charges65 | €42 | €80 | €272 | €89 | €379 | ▲ 328% |
| Profit (loss) for the period before taxes9903 | €-8k | €-1k | €-13k | €-16k | €-6k | ▲ 62.1% |
| Profit (loss) for the period9904 | €-8k | €-1k | €-13k | €-16k | €-6k | ▲ 62.1% |
| Profit (loss) for the period to be appropriated9905 | €-8k | €-1k | €-13k | €-16k | €-6k | ▲ 62.1% |
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Total assets20/58 | €4k | €2k | €30k | €28k | €22k | ▼ 21.3% |
| Formation expenses20 | €1k | €803 | €577 | €2k | €1k | ▼ 31.7% |
| Fixed assets21/28 | €1k | €1k | €27k | €26k | €20k | ▼ 21.8% |
| Intangible fixed assets21 | - | - | €25k | €24k | €19k | ▼ 18.3% |
| Tangible fixed assets22/27 | €1k | €1k | €2k | €1k | €646 | ▼ 47.0% |
| Plant, machinery and equipment23 | €1k | €1k | €700 | €366 | €33 | ▼ 91.0% |
| Furniture and vehicles24 | - | - | €1k | €853 | €613 | ▼ 28.1% |
| Financial fixed assets28 | - | - | €650 | €650 | - | - |
| Current assets29/58 | €1k | - | €2k | €935 | €1k | ▲ 11.5% |
| Cash at bank and in hand54/58 | €1k | - | €2k | €935 | €1k | ▲ 11.5% |
| Equity and liabilities | ||||||
| Total equity and liabilities10/49 | €4k | €2k | €30k | €28k | €22k | ▼ 21.3% |
| Equity10/15 | €-6k | €-7k | €-20k | €18k | €12k | ▼ 33.1% |
| Contributions10/11 | €2k | €2k | €2k | €56k | €56k | = |
| Outside capital11 | €2k | €2k | - | - | - | - |
| Other1109/19 | €2k | €2k | - | - | - | - |
| Profit (loss) carried forward14 | €-8k | €-9k | €-22k | €-38k | €-44k | ▼ 15.9% |
| Amounts payable17/49 | €10k | €9k | €50k | €10k | €10k | = |
| Amounts payable within one year42/48 | €10k | €9k | €50k | €10k | €10k | = |
| Financial debts43 | - | €14 | - | - | - | - |
| Credit institutions430/8 | - | €14 | - | - | - | - |
| Trade debts44 | €91 | €50 | €626 | - | - | - |
| Suppliers440/4 | €91 | €50 | €626 | - | - | - |
| Other amounts payable47/48 | €10k | €9k | €49k | €10k | €10k | = |
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €-8k | €-1k | €-13k | €-16k | €-6k | ▲ 62.1% |
| + Depreciation and write-downs630 | €602 | €560 | €3k | €7k | €8k | ▲ 7.8% |
| Operating cash flow (approximation) | €-7k | €-788 | €-9k | €-9k | €2k | ▲ 121% |
| Investment in fixed assets (approximation) | - | €-226 | €-30k | €-6k | €-2k | ▲ 60.7% |
| Change in cash | - | - | - | €-1k | €108 | ▲ 110% |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
28-08
NBB filing
Annual accounts filed
fiscal year 2025 · micro schema · 28 days late
2025
22-09
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema · 53 days late
2024
31-12
Financial
Weakest financial yearnet €-16k
Net result drops to €-16k, the lowest in the series; recovery starts the following year.
27-08
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema · 27 days late
2023
28-08
NBB filing
Annual accounts filed
fiscal year 2022 · full schema · 28 days late
30-05
NBB filing
Annual accounts filed
fiscal year 2021 · full schema · 303 days late
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
0 of 4 acts read
About the unread acts
We know of 4 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.
Directors · office · real estate
Directors
4 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Liège
Ground area
62 m²
Building footprint
67 m²
Volume, LiDAR
872 m³
Parcel 62813E0522/00B000, Wallonia · tallest building 14.9 m, ±5 floors. Linked by address, not a title deed.
1 parcel
Wallonia
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 62813E0522/00B000 | Wallonia | 61 m² | 1 · 67 m² | 14.9 m · 5 fl. |
Linked by address, not proof of ownership
Good to know
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector, comparable size
PHAGES ADEPTE
BE 1006.761.614
Vorst · Eq €11,976
ZYNTRA ADVISORY
BE 1027.548.021
Etterbeek · Eq €12,342
C-Path
BE 0762.683.482
Diepenbeek · Eq €11,862
SWANET BIOTECH
BE 1028.702.321
Gembloux · Eq €12,958
Gojie
BE 1018.681.528
Leuven · Eq €10,399
Of 762 companies in sector 72101 we hold annual accounts for 481. 146 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector
Identification & contact
Identification
Legal formPrivate limited company
Founded04-09-2020
Fiscal year end31-12
Activities, NACEBEL 2025
72101Research and development on biotechnology
21209Manufacture of basic pharmaceutical products and pharmaceutical preparations
46460Wholesale of pharmaceutical and medical goods
47730Retail sale of pharmaceutical products
Contact
Website
www.nanogyre.com
E-mail
nanogyre@gmail.com
Scores and ratios are computed by Checked and are not a credit decision.